Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

This review examines the potential of mesenchymal stem/stromal cells in treating and possibly preventing allergic diseases, and reports no new clinical results.

This study found that treating human dermal fibroblast cells with ginsenoside Rd increased the expression of mRNA associated with the dermal-epidermal junction, suggesting potential as an anti-aging cosmetic ingredient.

This review discusses the roles of the hairless (HR) protein as a corepressor, particularly its impact on RORα-mediated transcriptional repression, and reports no new experimental findings.

This study found that the Stem Cell Educator therapy improved hair regrowth and quality of life in patients with severe alopecia areata by restoring immune balance and protecting hair follicles from autoimmune damage.

OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.

This study found that patients with active severe alopecia areata exhibited decreased CD200 expression on T and B lymphocytes, which may be linked to an imbalance in Th1/Th2 immune equilibrium.

This study found that mesenchymal stem cell treatment alleviated atopic dermatitis-like symptoms in a mouse model by modulating immune and inflammatory responses, with gene expression changes suggesting pathways for potential personalized treatment approaches.

In this study, researchers developed a dissolvable microneedle patch combining HA-TEMPO and Portulaca oleracea L.-derived nanoparticles, which effectively reduced oxidative stress and inflammation in an atopic dermatitis model while restoring immune balance, suggesting a promising treatment strategy.

This study found that patients with alopecia areata and their healthy family members had elevated levels of Th1- and Th17-related cytokines, suggesting a genetic link in cytokine dysregulation.

This study suggests that allogenic human mesenchymal stem cell treatments have potential therapeutic effects by inducing immune tolerance and anti-inflammatory effects in severe alopecia areata patients.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This article reviews potential factors influencing Behçet's disease, like increased neutrophil functions, immunological changes, stress, and hormonal alterations, but it presents no new clinical results.

This study found that low concentrations of CBD promoted hair follicle growth, while higher concentrations induced hair follicle regression and increased cell death in an experimental setting.

Leflunomide is more likely to help treat alopecia areata than cause it.

Allergic contact dermatitis may promote hair growth by activating hair follicle stem cells.

This research investigated immune cell involvement in various types of inflammatory alopecia by analyzing gene expression data from scalp samples, revealing distinct cellular changes in conditions like Alopecia Areata, Frontal Fibrosing Alopecia, Lichen Planopilaris, and Central Centrifugal Cicatricial Alopecia, which may inform future therapeutic targets.

This study suggests that the outer root sheath of human hair follicles may act as a "metabolic center," capable of synthesizing glucose from lactate, which supports glycogen metabolism.

This study reported improvement in hair loss lesions in C3H/HeJ mice with alopecia areata following treatment with the CCR5 inhibitor maraviroc, alongside reduced infiltration of specific T cells in the lesions.

This study found that stimulating olfactory receptor OR2AT4 in human hair follicles with Sandalore® may slow catagen development and reduce keratinocyte apoptosis, suggesting potential implications for hair growth management.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

Alopecia areata severity is linked to increased TH1 and TH2 activity.

This study found that sex bias exists in dermatological research, with 60% of articles not reporting the sex of cells or animals and a disproportionate use of male cells and animals when known.

This review explores regenerative medicine approaches for vitiligo and alopecia areata, focusing on pathways for repopulating melanocytes and regrowing hair follicles, and summarizes potential treatments without reporting new clinical results.

This review highlights that frontal fibrosing alopecia’s increasing incidence may involve immune, genetic, hormonal, and environmental factors, yet its pathogenesis remains complex and not fully understood.

This study found that selectively targeting HDAC4 and HDAC7 in mice can reduce Th17 cell-mediated intestinal inflammation, suggesting a potential treatment approach for Th17-related inflammatory diseases like ulcerative colitis.

This study found that intramuscular anti-IFN-γ significantly stabilized and promoted hair regrowth in alopecia areata patients with patchy, progressive hair loss, whereas those with total baldness showed more limited improvement.

In this case report, a 62-year-old woman's persistent frontal fibrosing alopecia while on the psoriasis medication ustekinumab suggests that IL-12 and IL-23 inhibition may not be effective in treating this scarring alopecia, challenging the role of Th1 and Th17 pathways in its pathogenesis.

In this study, researchers found that patients with alopecia areata had a significant increase in NKG2D+CD4+ T cell levels in their blood compared to healthy controls.

This research suggests that innate lymphoid cells type 1 (ILC1) may contribute to the development of alopecia areata, alongside CD8+ T cells, by disrupting hair follicle immune privilege and promoting features of the disease.